- Home
- PBH vs KNSA Comparison
PBH vs KNSA Comparison
Compare PBH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBH | KNSA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PBH | KNSA |
|---|---|---|
| Price | $69.58 | $47.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $80.75 | $53.71 |
| AVG Volume (30 Days) | 361.8K | ★ 445.1K |
| Earning Date | 05-07-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 2.78 | 0.57 |
| Revenue | ★ $975,777,000.00 | $423,239,000.00 |
| Revenue This Year | N/A | $62.99 |
| Revenue Next Year | $2.15 | $33.30 |
| P/E Ratio | ★ $24.93 | $82.68 |
| Revenue Growth | 36.77 | ★ 56.60 |
| 52 Week Low | $57.25 | $18.26 |
| 52 Week High | $90.04 | $47.51 |
Technical Indicators
Market Signals| Indicator | PBH | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 67.87 |
| Support Level | $65.70 | $43.55 |
| Resistance Level | $67.74 | $47.51 |
| Average True Range (ATR) | 2.09 | 1.67 |
| MACD | 0.25 | 0.26 |
| Stochastic Oscillator | 99.83 | 95.93 |
Price Performance
Historical ComparisonAbout PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.